Evidence map›Paper›PMID 40737598›Full record

ArticleBlood2025

Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.

Ryo Akazawa, Takashi Mikami, Masaki Yamada, Itaru Kato, Hirohito Kubota, Satoshi Saida, Yoshinori Uchihara, Yuriko Ishikawa, Tatsuya Kamitori, Keiji Tasaka and 33 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Epstein-Barr Virus-Associated T/NK-Cell Neoplasms.Journal of medical virology · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors.

Ryo AkazawaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-8770-0493
Takashi MikamiDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0003-1846-4500
Masaki YamadaDivision of Infectious Diseases Pathogenesis, National Center for Child Health and Development, Tokyo, Japan.ORCID 0000-0002-3393-6943
Itaru KatoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-2932-4960
Hirohito KubotaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6935-5120
Satoshi SaidaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshinori UchiharaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-6006-4362
Yuriko IshikawaDepartment of Advanced Medicine for Virus Infections, National Center for Child Health and Development, Tokyo, Japan.ORCID 0000-0002-0223-6573
Tatsuya KamitoriDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0009-0003-0472-4663
Keiji TasakaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-2708-3876
Kiyotaka IsobeDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomoya IsobeDepartment of Haematology, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-3487-3307
Kazushi IzawaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0003-1080-0936
Katsutsugu UmedaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6844-2011
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0003-3136-5670
Keita JinnouchiDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.ORCID 0009-0009-4773-4849
Masahiro HirataDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0001-9211-0511
Masakazu FujimotoDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Tomoo DaifuDepartment of Pediatrics, Japanese Red Cross Otsu Hospital, Otsu, Japan.ORCID 0000-0002-9276-7019
Hiroo UenoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Seishiro NodomiDepartment of Pediatrics, Kurashiki Central Hospital, Okayama, Japan.ORCID 0009-0005-4402-7859
Machiko SawadaDepartment of Pediatrics, Kyoto Katsura Hospital, Kyoto, Japan.ORCID 0009-0006-0636-2709
Hisanori FujinoDepartment of Pediatrics, Osaka Red Cross Hospital, Osaka, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.ORCID 0000-0002-0476-4978
Mitsuteru HiwatariDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-3683-4472
Motohiro KatoDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-5145-1774
Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Ikumi KatanoLaboratory Animal Research Department, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.ORCID 0000-0001-7023-7677
Ryoji ItoLaboratory Animal Research Department, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.ORCID 0000-0003-2903-2332
Mamoru ItoLaboratory Animal Research Department, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.ORCID 0000-0002-5373-8223
Nobuyuki KakiuchiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0003-4893-5414
Masahiro M NakagawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6420-2555
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0001-6144-5845
Yoshitaka HondaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-6273-0648
Hiroyuki YoshitomiInstitute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan.
Hideki UenoInstitute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan.ORCID 0000-0001-7747-0738
Maho SatoDepartment of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan.
Satoru MiyanoDepartment of Integrated Analytics, M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.ORCID 0000-0002-1753-6616
Hironori HagaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0003-4322-9561
Akihisa SawadaDepartment of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan.ORCID 0000-0002-7906-8854
Ken-Ichi ImadomeDepartment of Advanced Medicine for Virus Infections, National Center for Child Health and Development, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-7778-5374
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-2452-6520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractChronic active Epstein-Barr virus (EBV) infection (CAEBV) is an orphan disease characterized by the proliferation and infiltration of EBV-infected T/natural killer (NK) cells into multiple organs. Although CAEBV is a heterogeneous disease with diverse clinical courses, its pathogenesis remains poorly understood. In this study, we explored the molecular mechanisms underlying CAEBV by performing a comprehensive multiomics analysis, including genome, transcriptome, epigenome, and single-cell transcriptome and surface proteome analyses, of 65 patients with CAEBV. Methylation analysis identified 2 distinct subtypes of NK cell-type CAEBV based on the CpG island methylator phenotype (CIMP). In CIMP-positive CAEBV, regions associated with enhancer of zeste homolog 2 binding sites and histone H3 lysine 27 trimethylation exhibited increased DNA hypermethylation, resulting in downregulation of tumor suppressor and antiherpesvirus genes. CIMP-positive CAEBV had a particularly poor prognosis and displayed a "neoplastic" phenotype with a DNA methylation pattern similar to that of extranodal NK/T-cell lymphoma, a higher tumor mutation burden, and frequent copy number alterations. In addition, both in vitro and in vivo functional assays demonstrated that 5-azacytidine, a hypomethylating agent, was a potentially effective agent for high-risk CIMP-positive CAEBV. Finally, we established a method to effectively detect EBV-infected cells in single-cell analysis, suggesting that EBV-infected NK cells have tissue-resident properties and that innate and adaptive immunity to EBV is compromised in patients with CAEBV. The present findings provide insight into the complex molecular features of CAEBV and suggest potential molecular therapies.

Indexed as

Epigenesis, GeneticEpstein-Barr Virus InfectionsHerpesvirus 4, HumanKiller Cells, NaturalAdolescentAdultChildChronic DiseaseCpG IslandsDNA MethylationFemaleHumansMaleMiddle AgedMultiomicsTranscriptome

Identifiers

PMID40737598
PMCPMC12824651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.